Headache and Dizziness as Prevailing Clinical Manifestations in Parkinson's Patients Following COVID-19
| Author | Mohammad Haddadi | en |
| Author | Yasamin Meamarzadegan | en |
| Author | Ali Vasheghani Farahani | en |
| Author | Alireza Etrati Kooshali | en |
| Author | Sheida Sarrafzadeh | en |
| Author | Parsa Ghafari | en |
| Author | Parsa Nobaveh | en |
| Author | Omid Salahi Ardekani | en |
| Author | Zahra Taghiabadi | en |
| Author | Saeed Motlaghzadeh | en |
| Author | Sepehr Damghani | en |
| Author | Arash Letafati | en |
| Orcid | Arash Letafati [0000-0002-0415-0239] | en |
| Issued Date | 2024-07-31 | en |
| Abstract | Background: The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has posed significant global health challenges, particularly for vulnerable populations. Objectives: This retrospective report from the Iranian Network for Research in Viral Diseases (INRVD) investigates the common clinical symptoms of COVID-19 in individuals with Parkinson's disease (PD). Research suggests neurological complications can occur during SARS-CoV-2 infection, but there are limited studies on neurological symptoms in PD patients with COVID-19. Given the probable heightened vulnerability of PD patients, evaluating clinical symptoms, especially neurological manifestations, is crucial. Methods: Data from 54 patients were collected from the INRVD from March 2020 to May 2021. Nasal, oropharyngeal, and nasopharyngeal swabs were collected from patients presenting with respiratory symptoms, following Iranian CDC guidelines. Following sample collection, RT-PCR assays were performed for COVID-19 confirmation. Statistical analysis was conducted using the Chi-square test and Fisher's exact test. Results: Among the 54 PD patients included in the study, 27 tested positive for COVID-19. Of the 54 subjects analyzed, 38.9% were female and 61.1% were male. Comparison of COVID-19 symptoms revealed a higher rate of sore throat (74%) and shortness of breath (81%) in the COVID-19 positive group as common clinical symptoms of the disease. Interestingly, higher rates of dizziness (67%) and headache (74%) were observed in PD patients with COVID-19. Conclusions: This study enhances our understanding of the diverse clinical manifestations of COVID-19 and its impact on individuals with underlying health conditions such as PD. The increased prevalence of neurological symptoms among PD patients underscores the need for further investigation to clarify whether these symptoms directly result from COVID-19 infection or if they may also be influenced by PD itself or its treatment. It is important to consider that while neurological symptoms in Parkinson's patients can be attributed to the underlying disorder or linked to medication and medical interventions, respiratory symptoms are typically associated with COVID-19. | en |
| DOI | https://doi.org/10.5812/ans-145699 | en |
| Keyword | Parkinson | en |
| Keyword | COVID-19 | en |
| Keyword | SARS-CoV-2 | en |
| Keyword | Respiratory Infection | en |
| Keyword | Neurologic Manifestations | en |
| Keyword | Headache | en |
| Publisher | Brieflands | en |
| Title | Headache and Dizziness as Prevailing Clinical Manifestations in Parkinson's Patients Following COVID-19 | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- ans-11-3-145699-publish-pdf.pdf
- Size:
- 708.02 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF